Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades últimos meses
Enero 2026
Eur J Clin Invest. 2026 Jan;56(1):e70167. doi: 10.1111/eci.70167. Epub 2026 Jan 3.
Autores:
Gabriela O Girón 1 2 , Sergi Otero 1 2 , Panagiota Efstathia Nikolaou 3 4 , Sebastià Alcover 1 5 , Lisaidy Ramos-Regalado 1 5 , Carlos Zaragoza 6 7 , Luca Liberale 8 9 , María Borrell-Pages 1 7 , Teresa Padró 1 7 , Rosa Suades 1 7 , Gemma Vilahur 1 7
Conclusion: The following review aims to provide a comprehensive overview of the latest evidence on the factors driving residual CV risk and the therapeutic interventions available to treat atherogenic dyslipidaemia beyond LDL-C reduction.
BMC Cardiovasc Disord. 2025 Dec 22;26(1):60. doi: 10.1186/s12872-025-05461-6.
Autores:
Ivette Cruz-Bautista 1 2 , Yuscely Flores-Jurado 3 , Antonio Barajas-Martínez 3 4 , Yulino Castillo-Núñez 5 , Daniel Elías-López 6 3 , María Alejandra Ramos-Guifarro 7 , Ramon Barrera-Cruz 8 , Lizbeth Ruilova-González 9 , Misael Aguilar-Panduro 3 , Liliana Muñoz-Hernández 3 10 , Roopa Mehta 6 3 , Raquel N Faradji 11 , Eduardo Márquez-Rodríguez 11 , Juan Carlos Garnica-Cuellar 11 , Samantha Gutiérrez-Morales 3 , José de Jesús Garduño-García 11 12 , José Alberto Ávila-Funes 13 , Arturo Guerra-López 14 , Alejo Diaz-Aragón 14 , Edith Ruiz-Gastelum 14 , Jorge Cossio-Aranda 15 , Raúl Velasco-Solorzano 16 , Pablo Corral 17 18 , Carlos O Mendívil 19 20 21 , Juan Patricio Nogueira 22 23 , Mario Morales-Esponda 6 , Carlos Alberto Aguilar-Salinas 3 4 ; Grupo Lípidos SMNE
Conclusión: Awareness and clinical use of Lp(a) testing among LATAM physicians remain limited and focused on high-risk scenarios. Improving test accessibility, providing clearer clinical guidelines, and reinforcing the evidence for Lp(a) as a therapeutic target may enhance its adoption and integration into cardiovascular risk assessment across the region.
Clin Res Cardiol. 2026 Feb;115(2):357-365. doi: 10.1007/s00392-025-02826-x. Epub 2025 Dec 16.
Autores:
Netanel Golan 1 , Ophir Freund 2 , Tamar Itach 1 , Yaron Arbel 3
Conclusión: In a large ambulatory and mostly healthy cohort, Lp(a) showed a strong predictive utility for cardiovascular events. These findings support the integration of Lp(a) into primary cardiovascular risk assessment and role in guiding emerging targeted therapies.
Clin Res Cardiol. 2026 Feb;115(2):322-334. doi: 10.1007/s00392-025-02751-z. Epub 2025 Aug 28.
Autores:
Oliver Weingärtner 1 2 , Simon Glück 3 4 , Karl Werdan 3 5 , Jessica Schorr 6 , Daniel Thieme 6 , Ana de la Llave 7 , Christian von Vultée 7 , Winfried Haerer 3 8
Conclusión: A large proportion of ASCVD patients in Germany are inadequately treated, with notable differences between GPs and OBCs. Additionally, gender and age-related disparities are evident. There is a clear need for these gaps to be addressed to improve cross-sectional patient care.
Phenomapping of subgroups in high-Lp(a) patients: a data-driven cluster analysis in RED-CARPET study
Clin Res Cardiol. 2026 Feb;115(2):255-265. doi: 10.1007/s00392-025-02669-6. Epub 2025 Jun 23.
Autores:
Shaozhao Zhang # 1 2 , Xiaoyu Lin # 3 , Rongjian Zhan # 4 , Huimin Zhou 1 2 , Yuhui Lai 1 2 , Mengting Huang 1 2 , Bingzhen Li 1 2 , Xinxue Liao 5 6 , Xiaodong Zhuang 7 8
Conclusión: Using a data-driven approach, high-Lp(a) patients can be stratified into four phenotypically distinct subgroups with different ASCVD risk.
Clin Res Cardiol. 2026 Feb;115(2):198-207. doi: 10.1007/s00392-024-02427-0. Epub 2024 Apr 15.
Autores:
Christoph Altmann 1 , Nelu-Adrian Burlacu 2 , Thomas Preuss 3 , Annett Hlousek 4 , Stephan Eddicks 2 ; MEDIAN Medical Board Cardiology
Conclusión: Lp(a) had been rarely assessed in acute management of aortic valve stenosis or premature myocardial infarction despite expanding scientific evidence and guideline recommendation. Given the above-average incidence of elevated Lp(a) levels, awareness for Lp(a) has to increase substantially to better identify and manage high-risk patients.
Eur J Clin Invest. 2026 Jan;56(1):e70127. doi: 10.1111/eci.70127. Epub 2025 Oct 3.
Autores:
Nadim Nasrallah 1 , Mark Atallah 1 , Tarek Harb 1 , Gary Gerstenblith 1 , Thorsten M Leucker 1
Conclusion: There are no currently approved lipid-lowering therapies that substantially reduce Lp(a) levels. Novel agents to lower Lp(a) include antisense oligonucleotides, small interfering ribonucleic acid and small molecules, all of which have shown promising results in phase 2 trials. Ongoing phase 3 trials will evaluate the causal relationship between Lp(a) and ASCVD, and whether lowering Lp(a) reduces cardiovascular outcomes.
Eur J Clin Invest. 2026 Jan;56(1):e70133. doi: 10.1111/eci.70133. Epub 2025 Oct 3.
Autores:
Mark Atallah 1 , Nadim Nasrallah 1 , Tarek Harb 1 , Gary Gerstenblith 1 , Thorsten M Leucker 1
Conclusión: While environmental factors such as inflammation and hormonal status can transiently modulate levels, genetic variation overwhelmingly dictates lifelong Lp(a) burden. As novel agents targeting Lp(a) enter late-stage clinical trials, mechanistic insights into Lp(a) biology will be essential to risk stratification and future clinical management.